Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eisai's Venture-Like R&D Starts To Produce Results, And Shorter Development Timelines

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Two years ago, Eisai Inc. restructured its R&D operations to create small, venture-like units to be both time- and cost-effective. Now the company is touting the plan's success, having shaved months off of many of its drug development timelines. The company recently filed approval submissions for first-in-class AMPA receptor antagonist perampanel more than a year ahead of schedule

You may also be interested in...

Eisai Manufacturing Changes Again, With Biogen Idec In The Mix

Eisai and Biogen Idec formed a manufacturing alliance for oral solids and parenteral capabilities, as Eisai continues to tinker with its global manufacturing model. Eisai also takes a new approach to academic partnerships with University College London for neurological targets.

Islands Dispute Hits Japan Device Sales In China While Pharma Less Affected

Both Japanese and Chinese device makers have reported lower sales and profits linked to a rift over disputed islands, potentially signaling a lengthy period of strained trade ties.

Eisai, Morphotek Gain Biologics Manufacturing Capability With New Plant Opening

Eisai gains biologics capability from subsidiary Morphotek’s new biologics manufacturing plant, as Eisai ramps up in emerging markets and transitions itself in a post-Aricept patent world.

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts